close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

TG Therapeutics, Inc. - Common Stock (NQ:TGTX)

31.95 +1.50 (+4.93%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 21, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about TG Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
News headline image
Crude Oil Falls Over 2%; ISM Services PMI Rises In April ↗
 
Via Benzinga
News headline image
TG Therapeutics Stock Tumbles After Q1 Earnings Fall Short Of Wall Street Estimates: But Retail’s Optimistic ↗
The company, however, raised its full-year 2025 global net revenue target to approximately $575 million, up from its previous guidance of $540 million. 
Via Stocktwits
News headline image
Earnings Scheduled For May 5, 2025 ↗
 
Via Benzinga
News headline image
Applying Mark Minervini’s growth stock checklist to TG THERAPEUTICS INC (NASDAQ:TGTX) ↗
A fundamental and technical analysis of (NASDAQ:TGTX): Is TG THERAPEUTICS INC (NASDAQ:TGTX) suited for high growth investing? 
Via Chartmill
News headline image
TG Therapeutics Inc (NASDAQ:TGTX): A Strong Minervini Trend Template Candidate ↗
TG Therapeutics Inc (NASDAQ:TGTX): A Strong Minervini Trend Template Candidate 
Via Chartmill
News headline image
Exploring high growth characteristics of TG THERAPEUTICS INC (NASDAQ:TGTX). ↗
UA fundamental and technical analysis of (NASDAQ:TGTX): nlocking the high Growth Potential of TG THERAPEUTICS INC (NASDAQ:TGTX). 
Via Chartmill
News headline image
Why TG Therapeutics Stock Was Soaring This Week ↗
Via The Motley Fool
News headline image
Expert Outlook: TG Therapeutics Through The Eyes Of 5 Analysts ↗
 
Via Benzinga
News headline image
TG Therapeutics Stock: A Deep Dive Into Analyst Perspectives (5 Ratings) ↗
 
Via Benzinga
News headline image
Price Over Earnings Overview: TG Therapeutics ↗
 
Via Benzinga
News headline image
Applying Mark Minervini’s growth stock checklist to TG THERAPEUTICS INC (NASDAQ:TGTX) ↗
Why TG THERAPEUTICS INC (NASDAQ:TGTX) qualifies as a high growth stock. A fundamental and technical analysis of (NASDAQ:TGTX). 
Via Chartmill
News headline image
IBD 50 Stock TG Therapeutics Rallies On A Setback For Chief Rival Roche ↗
The companies both have drugs that treat relapsing forms of multiple sclerosis. 
Via Investor's Business Daily
News headline image
Stock Of The Day: TG Therapeutics Breaks Out, May Head Higher ↗
TG Therapeutics has broken an important resistance level. There is a good chance that they will continue to move higher. 
Via Benzinga
News headline image
How does TG THERAPEUTICS INC (NASDAQ:TGTX) stack up against Mark Minervini’s strategy? ↗
A fundamental and technical analysis of (NASDAQ:TGTX): Is TG THERAPEUTICS INC (NASDAQ:TGTX) suited for high growth investing? 
Via Chartmill
News headline image
A Closer Look at TG Therapeutics's Options Market Dynamics ↗
 
Via Benzinga
News headline image
NASDAQ:TGTX stands out as a growth opportunity that won't break the bank. ↗
NASDAQ:TGTX is showing decent growth, but is still valued reasonably. 
Via Chartmill
News headline image
TG THERAPEUTICS INC (NASDAQ:TGTX), a growth stock which is not overvalued. ↗
Uncover the potential of TG THERAPEUTICS INC, a growth stock reasonably priced. NASDAQ:TGTX is excelling in growth aspects, maintaining a healthy financial position, and still offers an attractive... 
Via Chartmill
News headline image
Bilibili, MARA And ZEEKR Are Among Top 8 Mid-Cap Gainers Last Week (Mar 3-Mar 7): Are The Others In Your Portfolio? ↗
Top mid-cap stocks jumped up to 23.87%. Some reasons include strong gold/silver, better financial results, and market strength. 
Via Benzinga
News headline image
Retail Bets TG Therapeutics Stock Can Sustain Post-Earnings Gains Throughout The Week ↗
Annual revenue from its MS drug, Briumvi, more than tripled, with U.S. net product revenue reaching $103.6 million in the fourth quarter and $310 million for the full year. 
Via Stocktwits
News headline image
Stocks Pivot Lower On Trade Fears, Manufacturing Data ↗
Despite earlier indicating a strong start to March, stocks are lower this afternoon amid trade war concerns. 
Via Talk Markets
Topics Stocks / Equities World Trade
News headline image
TG Therapeutics, A New Leaderboard Stock, Skyrockets 17% On Sales Beat, Bullish Guide ↗
The company has gained notoriety for its multiple sclerosis treatment. 
Via Investor's Business Daily
Topics Earnings
News headline image
Earnings Scheduled For March 3, 2025 ↗
 
Via Benzinga
News headline image
10 Health Care Stocks Whale Activity In Today's Session ↗
 
Via Benzinga
News headline image
8 Health Care Stocks Whale Activity In Today's Session ↗
 
Via Benzinga
News headline image
What's Going On With TG Therapeutics Stock Tuesday? ↗
TG Therapeutics Inc (NASDAQ:TGTX) shares are trading higher. The company on Tuesday provided guidance for the fourth quarter and full-year 2024. 
Via Benzinga
News headline image
10 Health Care Stocks Whale Activity In Today's Session ↗
 
Via Benzinga
News headline image
Stock Market Surges To Highs On Trump Election; Fed Cuts Rates, Palantir Soars: Weekly Review ↗
A Fed rate cut and a slew of big earnings reports filled out a busy week. 
Via Investor's Business Daily
Topics Economy Government
News headline image
TG Therapeutics Crashes — Reversing A Breakout — On Its Mixed Third-Quarter Results ↗
The company raised its sales outlook for the year, though, following stronger-than-expected revenue from its only product. 
Via Investor's Business Daily
News headline image
Why Yum China Shares Are Trading Higher By Around 8%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
Napco Security Technologies Posts Downbeat Results, Joins Centrus Energy, Constellation Energy And Other Big Stocks Moving Lower In Monday's Pre-Market Session ↗
 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today